ONC – BeOne Medicines Ltd ADR

ONC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.09

Margin Of Safety %

-3

Put/Call OI Ratio

1.15

EPS Next Q Diff

-0.29

EPS Last/This Y

-1.37

EPS This/Next Y

2.87

Price

308.74

Target Price

412.14

Analyst Recom

1.23

Performance Q

-16.29

Upside

-49.5%

Beta

0.51

Ticker: ONC

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-23	ONC	299.55	1.35	10.35	3382
2026-04-24	ONC	300.76	1.46	0.50	3604
2026-04-27	ONC	298.92	1.46	0.25	3605
2026-04-28	ONC	297.92	1.45	1.25	3611
2026-04-29	ONC	290.61	1.44	0.33	3614
2026-04-30	ONC	295.31	1.24	0.00	3340
2026-05-01	ONC	293.43	1.23	999.99	2877
2026-05-04	ONC	297.15	1.23	0.60	2878
2026-05-05	ONC	297.38	1.23	0.02	2880
2026-05-06	ONC	313.24	1.24	0.31	2865
2026-05-07	ONC	317.24	1.23	0.27	2883
2026-05-08	ONC	311.96	1.23	0.62	2883
2026-05-11	ONC	310.58	1.18	0.05	2866
2026-05-12	ONC	314.82	1.15	1.60	2820
2026-05-13	ONC	316.07	1.15	0.33	2846
2026-05-14	ONC	304.48	1.11	0.56	2845
2026-05-15	ONC	293.09	1.09	3.53	2815
2026-05-18	ONC	293.31	1.28	0.04	1489
2026-05-19	ONC	297.35	1.23	0.13	1518
2026-05-20	ONC	309.02	1.19	0.24	1543
2026-05-21	ONC	309.67	1.18	0.17	1556
2026-05-22	ONC	310.63	1.15	1.60	1575
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-23	ONC	299.89	8351.1	282.6	5.52
2026-04-24	ONC	300.53	8351.1	299.1	5.61
2026-04-27	ONC	299.77	8595.0	307.3	5.73
2026-04-28	ONC	298.57	8595.0	307.5	5.73
2026-04-29	ONC	290.90	8595.0	295.5	5.73
2026-04-30	ONC	296.88	7957.5	310.5	5.67
2026-05-01	ONC	294.02	7957.5	327.4	5.67
2026-05-04	ONC	297.19	7957.5	337.0	5.67
2026-05-05	ONC	296.65	7957.5	321.1	5.67
2026-05-06	ONC	311.78	7957.5	367.8	5.67
2026-05-07	ONC	316.66	7957.5	408.6	5.67
2026-05-08	ONC	312.76	53.7	40.4	5.67
2026-05-11	ONC	310.28	53.7	68.8	5.67
2026-05-12	ONC	314.61	84.4	74.7	6.12
2026-05-13	ONC	315.96	84.4	78.4	6.12
2026-05-14	ONC	305.47	84.4	69.3	6.12
2026-05-15	ONC	294.06	84.4	53.4	6.12
2026-05-18	ONC	293.04	84.4	72.5	6.12
2026-05-19	ONC	296.18	84.4	83.0	6.12
2026-05-20	ONC	307.55	84.4	146.2	6.56
2026-05-21	ONC	309.19	84.4	124.7	6.56
2026-05-22	ONC	308.74	84.4	109.2	6.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-23	ONC	-18.77	1.00	1.20
2026-04-24	ONC	-18.77	1.00	1.20
2026-04-27	ONC	-18.77	0.91	1.14
2026-04-28	ONC	-18.77	0.91	1.14
2026-04-29	ONC	-18.77	0.91	1.14
2026-04-30	ONC	-18.77	0.91	1.14
2026-05-01	ONC	-18.77	0.91	1.14
2026-05-04	ONC	-18.77	1.06	1.14
2026-05-05	ONC	-18.77	1.06	1.14
2026-05-06	ONC	-18.77	1.06	1.14
2026-05-07	ONC	-18.77	1.06	1.14
2026-05-08	ONC	-18.77	1.06	1.13
2026-05-11	ONC	-18.73	1.17	1.13
2026-05-12	ONC	-18.73	1.17	1.09
2026-05-13	ONC	-18.73	1.17	1.09
2026-05-14	ONC	-18.73	1.17	1.09
2026-05-15	ONC	-16.64	1.17	1.09
2026-05-18	ONC	-16.68	1.46	1.09
2026-05-19	ONC	-17.49	1.46	1.09
2026-05-20	ONC	-16.97	1.46	1.09
2026-05-21	ONC	-16.97	1.46	1.09
2026-05-22	ONC	-16.97	1.46	1.09
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

1.96

Avg. EPS Est. Current Quarter

1.55

Avg. EPS Est. Next Quarter

1.67

Insider Transactions

-16.97

Institutional Transactions

1.46

Beta

0.51

Average Sales Estimate Current Quarter

1594

Average Sales Estimate Next Quarter

1667

Fair Value

298.87

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

27.6

Max Drawdown 5-Year %

-70

Target Price

412.14

P/E

69.23

Forward P/E

32.45

PEG

0.46

P/S

5.51

P/B

7.24

P/Free Cash Flow

28.4

EPS

4.48

Average EPS Est. Cur. Y

6.69

EPS Next Y. (Est.)

9.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.94

Relative Volume

0.76

Return on Equity vs Sector %

-16.3

Return on Equity vs Industry %

-0.7

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

1.08

EBIT Estimation

109.2

◆ ONC Healthcare

$310.25

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

3/20

Pullback

13/25

Volume

9/15

Valuation

15/20

TP/AR

2/10

Options

2/10

RSI

Range 1M

59%

Sup Dist

1.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

29/30

Estimates

5/20

Inst/Vol

4/15

Options

3/10

EPS Yr

149.7%

EPS NY

45.6%

52W%

49.1%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +9.4% upside

Quality

14/30

Valuation

5/30

Growth

21/25

Stability

6/10

LT Trend

0/5

Upside

+9.4%

Quality

MoS

-3%

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

ONC – BeOne Medicines Ltd ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ONC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y